Korro Bio Inc. (KRRO) - חוב להון עצמי

Korro Bio, Inc. (KRRO) is implementing automated laboratory systems to accelerate the screening of anti-tumor agents. The business model relies on venture capital investments and technological leaps in therapy rather than macroeconomics. The total debt-to-equity ratio stands at 0.40, which the price action on this chart links to high margins driven by a global network of biopharma contractors and the complex cold-chain logistics of RNA products.

Investors expect high capitalization with minimal liabilities from biotech startups. This indicator is calculated as the ratio of total borrowed funds to equity. By analyzing changes in the total debt-to-equity ratio, one can assess the degree of financial leverage and the risk of bankruptcy. For Korro Bio, Inc. (KRRO) and its OPERA platform, low leverage is critically important during the lengthy development of RNA drugs. The stability of this ratio confirms the sustainability of innovation funding.